The project involves research and development of pharmaceutical products, specifically including pellets, granules, powders, tablets, and capsules.
The total estimated cost of the project is ₹35,00,00,000/- (Rupees Thirty Five Crore Only).
The Company has authorized Mrs. Chaitali Shah, Director, to execute the agreement and undertake all necessary acts, deeds, and things on behalf of the wholly owned subsidiary. This includes signing and executing documents and completing all formalities in connection with the project.
The agreement was executed on 04/11/2026, as detailed in the Annexure A disclosure required under Regulation 30 of the SEBI (LODR) Regulations, 2015.
Authorized Representative
Mrs. Chaitali Shah, Director, was authorized to execute the agreement and complete all formalities.
#BacilPharma #RDAgreement #SEBIDisclosure #RegulatoryCompliance #PharmaceuticalR&D